SP
BravenNow
Feld, Becton Dickinson’s EVP, sells $13,638 in stock
| USA | economy | ✓ Verified - investing.com

Feld, Becton Dickinson’s EVP, sells $13,638 in stock

#Becton Dickinson #BDX #Michael Feld #Insider Trading #Stock Sale #Rule 10b5-1 #Financial Results #Revenue #Earnings Per Share #Debt Tender Offers #Investment Targets #RBC Capital #Piper Sandler #Jefferies

📌 Key Takeaways

  • Michael Feld, Becton Dickinson EVP, sold 75 shares worth $13,638 on Feb 26, 2026.
  • The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in 2025.
  • Becton Dickinson's Q1 2026 results exceeded expectations: revenue $5.25 billion (0.4% YoY), EPS $2.91.
  • Becton Dickinson announced debt tender offers up to $1.6 billion.
  • RBC Capital, Piper Sandler, and Jefferies adjusted their price targets for BDX.

📖 Full Retelling

Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE:BDX), sold 75 shares of the company’s common stock for $13,638 on February 26, 2026. The sale, executed under a pre-arranged Rule 10b5-1 trading plan adopted in 2025, means he now directly owns 21,308 shares. This occurred after Becton Dickinson reported fiscal first-quarter 2026 results exceeding expectations, with revenue of $5.25 billion (0.4% year-over-year increase) and earnings per share at $2.91, both surpassing estimates. The company also announced debt tender offers. Several investment firms have adjusted their price targets for BDX in response to these developments.

🏷️ Themes

Insider Trading, Financial Performance, Corporate Finance, Investment Banking, Stock Market

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
BD (company)

BD (company)

American biotechnology Company

Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas. BD is ranked #211 in the 2...

View Profile → Wikipedia ↗

BDX

Topics referred to by the same term

BDX may refer to:

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile

Deep Analysis

Why It Matters

The sale by a high-ranking executive at Becton Dickinson could signal their personal assessment of the company's future prospects. It may be interpreted by investors as a lack of confidence or a strategic move based on personal financial planning, potentially influencing market perception of the company.

Context & Background

  • Executive stock sales are often closely watched by investors.
  • Becton Dickinson recently reported positive financial results.
  • The company is undergoing strategic financial maneuvers including debt tender offers.

What Happens Next

Investors will likely monitor Becton Dickinson's future performance and any further executive stock transactions. Analyst ratings and price targets may continue to be adjusted based on the company's progress and broader market conditions.

Frequently Asked Questions

What is a Rule 10b5-1 trading plan?

A Rule 10b5-1 plan is a pre-arranged trading plan that allows executives to automate stock sales, reducing the risk of insider trading accusations.

How does this relate to BDX's recent financial performance?

The stock sale occurs after Becton Dickinson reported better-than-expected earnings and announced debt reduction plans. The sale may be interpreted in light of these developments.

What do the analysts' target adjustments indicate?

The analysts' adjusted price targets reflect varying perspectives on the company's future growth potential, with Jefferies maintaining a 'Buy' rating despite lowering their target.

Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Wall Street posts worst month since March amid geopolitics, trade, and AI fears Gold prices climb, with spot gold set for a monthly gain of more than 8% OpenAI hits $730B valuation as Amazon, NVIDIA, and SoftBank inject $110B Where Bernstein sees gold prices ending the decade after latest update (South Africa Philippines Nigeria) Feld, Becton Dickinson’s EVP, sells $13,638 in stock By Investing.com Insider Trading Published 02/27/2026, 07:19 PM Feld, Becton Dickinson’s EVP, sells $13,638 in stock 0 BDX -0.10% Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE:BDX) , sold 75 shares of the company’s common stock at $181.84 on February 26, 2026. The total value of the transaction amounted to $13,638. Following the transaction, Feld directly owns 21,308 shares of Becton Dickinson & Co, which includes adjustments related to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Feld on February 7, 2025. In other recent news, Becton Dickinson reported fiscal first-quarter 2026 results that exceeded expectations, with revenue reaching $5.25 billion, marking a 0.4% year-over-year increase. This performance surpassed Wall Street’s estimates of $5.15 billion and the company’s own guidance for a low-single-digit decline. Earnings per share came in at $2.91, beating consensus by $0.10. Alongside these results, Becton Dickinson announced tender offers to purchase up to $1.6 billion of its outstanding debt securities across 15 different series. RBC Capital, Piper Sandler, and Jefferies have all adjusted their price targets for the company. RBC Capital lowered its target to $172 while maintaining a Sector Perform rating, Piper Sandler reduced its target to $170 with a Neutral rating, and Jefferies set a new target of $190 while maintaining a Buy rating. These developme...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine